Zobrazeno 1 - 4
of 4
pro vyhledávání: '"I.V. Ishmatova Ishmatova"'
Autor:
T.Yu. Semiglazova Semiglazova, L.V. Filatova Filatova, I.V. Ishmatova Ishmatova, M. S. Motalkina, A.K. Kovyazin Kovyazin, Yu.A. Chudinovskikh Chudinovskikh, E.V. Cherkasova Cherkasova, S.A. Shalaev Shalaev, S.A. Volchenkov Volchenkov, A.A. Zverkova Zverkova, I.S. Zyuzgin Zyuzgin
Publikováno v:
Pharmateca. :42-50
Autor:
Yu.A. Oleinik Oleinik, I.V. Ishmatova Ishmatova, M. S. Motalkina, P.S. Shilo Shilo, I.S. Zyuzgin Zyuzgin, Yu.A. Chudinovskikh Chudinovskikh, T.Yu. Semiglazova Semiglazova, L.V. Filatova Filatova, E.V. Kharchenko Kharchenko
Publikováno v:
Pharmateca. :26-32
Autor:
Svetlana Kuleva, Tatyana Semiglazova, A. Subora, Margarita Motalkina, Yevgeniya Kharchenko, Sergey Alekseev, I.V. Ishmatova Ishmatova, Yuliya Oleynik, Ilya Zyuzgin, Yuliya Chudinovskikh, Sergey Shalaev, Filatova Lv, Polina Shilo
Publikováno v:
Problems in oncology. 64:414-418
High dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is suggested as the standard of treatment of patients with relapsed or refractory Hodgkin’s lymphoma (HL) providing long-term disease-free survival in over 50 % of patie
Autor:
Sergey Alekseev, I.V. Ishmatova Ishmatova, Ilya Zyuzgin, Anna Artemeva, Polina Shilo, Filatova Lv, Tatyana Semiglazova, Yevgeniya Kharchenko, Margarita Motalkina
Publikováno v:
Problems in oncology. 63:326-328
Currently there is no single approach to treatment for aggressive diffuse large-cell B-cell lymphoma (Double-HIT and Triple-HIT). Accumulated world data remain controversial and, given the unfavorable prognosis in this subgroup, high-dose chemotherap